NEUTRISCI PARTNER TABLETZ LLC LAUNCHES WEBSITE AND SOCIAL MEDIA PLATFORMS TO CONQUER JAPANESE CBD MARKET
Vancouver, British Columbia – October 8, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company developing products for the nutraceutical industry, in conjunction with its partner, Tabletz LLC., is very pleased to announce details of the TABLETZ brand that will be launched in Japan this month (October 2020).
The Tabletz product line consists of (2) SKU’s each offering (3) unique flavor options. The 1st SKU is described as a “Daily” stick containing (3) 14 mg CBD TABLETZ, as shown. The 3 Tabletz stick will be sold for $8.00 USD. The 2nd SKU is a “Travel” stick containing (7) 14mg CBD TABLETZ and will be sold for $16.00 USD; flavor profiles for both SKU’s will be Berry, Lemon and Mint.
Tabletz LLC., also plans to launch a 500 mg bulk bottle containing (35) 14 mg Tabletz in the coming weeks. Both NeutriSci and Tabletz LLC. are working towards including the new bulk bottle with the opening order of the Tabletz sticks. Approved packaging of this product line, including pricing, will be completed in the coming days. Initial purchase orders for the bulk product and production scheduling will be released upon finalization of the packaging.
The official website is: www.tabletz-cbd.com
The official Instagram channel is: www.instagram.com/tabletzcbd
Glen Rehman, CEO of NeutriSci, stated: “After many months of hard work, we are very happy for Tabletz LLC and are anxiously awaiting the launch of the product line, which will have a soft-launch at an invite only media VIP event today and tomorrow (October 8th and 9th) that will not only showcase the product line but is also the first official unveiling of the products to the Japanese marketplace. Together, we have a long-term commitment towards making the Tabletz brand a smashing success with consumers in Japan.”
NEUTRISCI INTERNATIONAL INC.
Tel: (403) 264-6320
For investor inquiries, please contact email@example.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberry extract (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
For more information, please visit: www.neutrisci.com.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.